Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 May;80(5):e64.
doi: 10.1136/annrheumdis-2020-218196. Epub 2020 Jun 16.

Response to: 'COVID-19 in patients with rheumatological diseases treated with Anti-TNF' by Brito et al and 'Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot spot' versus in US 'hot spot': similarities and differences' by Zhao et al

Kristin M D'Silva  1 , Naomi Serling-Boyd  1 , Rachel Wallwork  1 , Tiffany Hsu  2 , Jeffrey A Sparks  2 , Zachary Scott Wallace  3
Affiliations
Comment

Response to: 'COVID-19 in patients with rheumatological diseases treated with Anti-TNF' by Brito et al and 'Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot spot' versus in US 'hot spot': similarities and differences' by Zhao et al

Kristin M D'Silva et al. Ann Rheum Dis. 2021 May.
No abstract available

Keywords: autoimmunity; biological therapy; epidemiology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: JAS reports grants from NIH/NIAID/Autoimmune Centers of Excellence, the Rheumatology Research Foundation, the Brigham Research Institute, and the R. Bruce and Joan M. Mickey Research Scholar Fund as well as personal fees from Bristol-Myers Squibb, Gilead, Inova, Janssen, and Optum. ZSW reports grants from NIH/NIAMS (K23AR073334 and L30 AR070520) and Bristol-Myers Squibb.

Comment on

References

    1. Brito C, Paiva J, Pimentel F, et al. COVID-19 in patients with rheumatological diseases treated with anti-TNF. Ann Rheum Dis 2021;80:e62. - PubMed
    1. Zhao J, Pang R, Wu J, et al. Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China ‘hot spot’ vesus US ‘hot spot’: similarities and differences. Ann Rheum Dis 2021;80:e63. - PubMed
    1. D’Silva KM, Serling-Boyd N, Wallwork R, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’. Ann Rheum Dis 2020;79:1156–62. - PMC - PubMed
    1. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis 2020;79:859–66. - PMC - PubMed
    1. Mikuls TR, Johnson SR, Fraenkel L, et al. American College of rheumatology guidance for the management of adult patients with rheumatic disease during the COVID-19 pandemic. Arthritis Rheumatol 2020. doi:10.1002/art.41301. [Epub ahead of print: 29 Apr 2020]. - DOI - PubMed

Substances